Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health, Beauty And Wellness News: Ocuvite Blue Light, NIH Herbal App

This article is powered by The Rose Sheet

Executive Summary

Nutraceutical Corp. refutes California lead claim; CRN Conference, Workshop registration open; GMA appoints Freeman to helm; Ocuvite Blue Light for digital protection; and NIH app for herbals.

You may also be interested in...



Bausch Boosts Consumer Growth Platform With Ocuvite Eye Performance

In a market expected to reach $2.85bn in worldwide sales in 2024, Bausch Health's Bausch + Lomb business launches Ocuvite Eye Performance, formulated to help strengthen the macula and protect the eye from stressors such as sun light and blue light emitted from digital devices, in the US while considering expanding distribution to other countries.

Bausch Health Boosts Ad Spending For Expanding OTC Eye Care Lineup

"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.

Bausch Health Boosts Ad Spending For Expanding OTC Eye Care Lineup

"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel